Release date: 2017-02-17 One of the most promising new ways to slow the spread of HIV is pre-exposure prophylaxis (PrEP), which is taken once a day and can be taken by people without HIV. However, this strategy is only effective when people at risk of HIV infection are involved in preventive care and are actually taking the drug. In clinical practice, this is often tricky. In a new article in the AIDS journal, a research team at Brown University used their experience in studying the PrEP program to propose a new system to understand and evaluate the implementation of PrEP in clinical practice. By dividing the process into nine specific steps, researchers and clinical providers can correctly assess patients to help them stay HIV-negative. Dr. Chen Ming, MD, assistant professor of medicine and medical doctor at Brown Warren Alpert Medical School, said: "It is useful to treat PrEP as a continuum." Doctors across the country found that in early PrEP projects, it was sometimes difficult to maintain patient care and ensure that they followed or “persisted†medication. In the early academic trials of PrEP, adherence to drugs was promising, but the results of the research often differed from the real situation. Nunn said: "Important research trials and CDC-funded demonstration projects have proven that PrEP is absolutely effective in reducing HIV access." In a study that analyzed the progress of urban clinical plans in Rhode Island, Mississippi and Missouri last year, Nunn, Chan and colleagues found that only about 60% of patients who started registering with PrEP were still nursing after 6 months. . Nine PrEP steps The nine steps proposed are: (1) identifying individuals at the highest risk of HIV infection; (2) raising HIV risk awareness; (3) raising PrEP awareness; (4) promoting PrEP access; and (5) connecting to PrEP care (6) Prescribe PrEP; (7) Start PrEP; (8) Persist in PrEP; (9) Preserve PrEP care of the individual. In many of the emerging research literature in the field, scholars have seen progress in four steps (identifying people at risk, increasing PrEP knowledge, ensuring access to PrEP, and ensuring drug compliance), but Chan and Nunn say the process is too Many gaps, many problems have been missed. “This process is more complicated and subtle than many people think,†says Chan. For example, even if some patients have been identified as at risk of contracting HIV and already know what PrEP is, they may not know enough about their AIDS risk to take PrEP. PrEP does have side effects and can be expensive. In another example, the researchers noted that compliance does not always assess the most accurate measure of success of PrEP's public health impact. They say that care retention may be more important. In future research, Nunn said that she and her colleagues will focus on when people are no longer being cared for and why. In some cases, she said, patients lose follow-up and do not take medication because they may lose health insurance or do not have enough support services to overcome other obstacles to taking PrEP medication. As a result, Nunn advocates funding for PrEP to help high-risk patients overcome barriers such as inadequate insurance and continue to participate in preventive care. Source: Noble Biochemical industry Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com
Researchers have proposed a new approach to HIV prevention based on drug assessment